ArticleCancer science2025

Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.

Yusuke Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.